patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1 value | histology stringclasses 3 values | stage_at_diagnosis stringclasses 3 values | driver_mutation stringclasses 7 values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2 values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6 values | overall_survival_months float64 4 83 | censored bool 2 classes | msi_status stringclasses 2 values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_547503 | REC_0000701 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 4.8 | 67 | female | 1 | 42 | 8.4 | 8 | pembrolizumab 200 mg q3w | 15.9 | false | MSS | 2026-03-15T05:35:57.009007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772372 | REC_0000702 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.3 | 65 | male | 0 | 17 | 3.6 | 7 | pembrolizumab 200 mg q3w | 10.4 | false | MSS | 2026-03-15T05:35:57.009240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394459 | REC_0000703 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 10.1 | 58 | female | 1 | 16 | 6.1 | 6 | osimertinib 80 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:57.009530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743253 | REC_0000704 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 9.6 | 86 | male | 2 | 48 | 5.4 | 8 | carboplatin + paclitaxel + pembrolizumab | 18.3 | false | MSS | 2026-03-15T05:35:57.009764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372464 | REC_0000705 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 16.1 | 72 | female | 1 | 13 | 6.6 | 5 | alectinib 600 mg BID | 14.5 | true | MSS | 2026-03-15T05:35:57.009996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779076 | REC_0000706 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 18.5 | 67 | female | 1 | 13 | 5.3 | 6 | sotorasib 960 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:35:57.010227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214205 | REC_0000707 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 36 | 12.1 | 59 | female | 0 | 25 | 6.5 | 2 | entrectinib 600 mg daily | 18.5 | true | MSS | 2026-03-15T05:35:57.010464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614615 | REC_0000708 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 8.3 | 62 | male | 1 | 6 | 4.5 | 2 | pembrolizumab 200 mg q3w | 21.8 | true | MSS | 2026-03-15T05:35:57.010698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849578 | REC_0000709 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.6 | 56 | female | 1 | 1 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 15 | false | MSS | 2026-03-15T05:35:57.010931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801336 | REC_0000710 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 12 | 69 | female | 1 | 10 | 5.2 | 1 | osimertinib 80 mg daily | 4.4 | false | MSS | 2026-03-15T05:35:57.011162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725114 | REC_0000711 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 14.6 | 61 | male | 1 | 16 | 5.3 | 6 | pembrolizumab 200 mg q3w | 9 | false | MSS | 2026-03-15T05:35:57.011395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925602 | REC_0000712 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 14.4 | 73 | male | 3 | 19 | 6.3 | 2 | entrectinib 600 mg daily | 17.8 | true | MSI-H | 2026-03-15T05:35:57.011667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890524 | REC_0000713 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.1 | 75 | female | 2 | 14 | 4.6 | 4 | sotorasib 960 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.011909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169173 | REC_0000714 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.1 | 73 | female | 1 | 16 | 5.3 | 7 | entrectinib 600 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:57.012193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448495 | REC_0000715 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 4.1 | 65 | female | 0 | 6 | 3.1 | 6 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:57.012437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955055 | REC_0000716 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 16.2 | 67 | male | 0 | 16 | 3.5 | 5 | sotorasib 960 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:57.012750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191289 | REC_0000717 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 9.3 | 69 | female | 0 | 18 | 4.9 | 6 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:35:57.012990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802831 | REC_0000718 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 6 | 52 | female | 0 | 6 | 4.8 | 0 | pembrolizumab 200 mg q3w | 23.8 | false | MSS | 2026-03-15T05:35:57.013222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705293 | REC_0000719 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 32 | 13.1 | 67 | female | 1 | 18 | 6.2 | 2 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:57.013461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946282 | REC_0000720 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 12.9 | 67 | female | 0 | 11 | 5.6 | 1 | sotorasib 960 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:57.013697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870021 | REC_0000721 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 18.3 | 60 | female | 0 | 11 | 6.5 | 6 | alectinib 600 mg BID | 10.8 | false | MSI-H | 2026-03-15T05:35:57.013934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723724 | REC_0000722 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 13.9 | 73 | female | 2 | 13 | 6.7 | 1 | sotorasib 960 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:35:57.014164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849022 | REC_0000723 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 16.6 | 60 | male | 1 | 8 | 4 | 2 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:57.014426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543007 | REC_0000724 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 11.5 | 64 | female | 1 | 13 | 4.8 | 5 | sotorasib 960 mg daily | 7.8 | false | MSI-H | 2026-03-15T05:35:57.014674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709671 | REC_0000725 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12 | 76 | female | 1 | 20 | 4.2 | 6 | osimertinib 80 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:57.015003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918853 | REC_0000726 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 34 | 12.4 | 61 | male | 0 | 13 | 3.8 | 8 | entrectinib 600 mg daily | 14.6 | false | MSS | 2026-03-15T05:35:57.015243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707843 | REC_0000727 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.5 | 59 | female | 1 | 40 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.4 | true | MSS | 2026-03-15T05:35:57.015521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110201 | REC_0000728 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 17.2 | 71 | female | 2 | 23 | 5.6 | 1 | osimertinib 80 mg daily | 13 | false | MSI-H | 2026-03-15T05:35:57.015762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696028 | REC_0000729 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 14.5 | 72 | female | 3 | 18 | 5.1 | 2 | pembrolizumab 200 mg q3w | 20.5 | false | MSS | 2026-03-15T05:35:57.016284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531628 | REC_0000730 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 15.2 | 52 | male | 0 | 6 | 3.8 | 4 | entrectinib 600 mg daily | 19.3 | false | MSS | 2026-03-15T05:35:57.016570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527719 | REC_0000731 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.4 | 63 | male | 1 | 16 | 5.7 | 6 | osimertinib 80 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:57.016825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189876 | REC_0000732 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 9.2 | 57 | female | 1 | 10 | 7.1 | 1 | osimertinib 80 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:57.017081+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363029 | REC_0000733 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 14.2 | 67 | female | 1 | 13 | 6.4 | 1 | pembrolizumab 200 mg q3w | 14.7 | true | MSI-H | 2026-03-15T05:35:57.017339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295391 | REC_0000734 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.7 | 72 | male | 2 | 17 | 6.7 | 4 | pembrolizumab 200 mg q3w | 7.2 | true | MSS | 2026-03-15T05:35:57.017602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248162 | REC_0000735 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 13.1 | 57 | male | 1 | 17 | 5.8 | 9 | alectinib 600 mg BID | 13.2 | true | MSS | 2026-03-15T05:35:57.017861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286978 | REC_0000736 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 8 | 70 | female | 2 | 14 | 6.5 | 1 | alectinib 600 mg BID | 24.8 | true | MSS | 2026-03-15T05:35:57.018097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970651 | REC_0000737 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 5.3 | 64 | male | 1 | 69 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:57.018337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820896 | REC_0000738 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 6.3 | 67 | male | 1 | 9 | 5 | 6 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:57.018576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538851 | REC_0000739 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 10.2 | 60 | female | 0 | 14 | 4.8 | 2 | osimertinib 80 mg daily | 20.7 | false | MSS | 2026-03-15T05:35:57.018824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795215 | REC_0000740 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.5 | 80 | female | 0 | 38 | 6.5 | 5 | pembrolizumab 200 mg q3w | 6.2 | false | MSS | 2026-03-15T05:35:57.019075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617162 | REC_0000741 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 14.1 | 62 | female | 1 | 18 | 6.3 | 5 | alectinib 600 mg BID | 15.7 | false | MSI-H | 2026-03-15T05:35:57.019335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679125 | REC_0000742 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.6 | 89 | female | 0 | 37 | 7.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.9 | true | MSS | 2026-03-15T05:35:57.019772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396761 | REC_0000743 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 6.7 | 60 | female | 1 | 14 | 4.8 | 4 | entrectinib 600 mg daily | 6.9 | true | MSS | 2026-03-15T05:35:57.020062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318229 | REC_0000744 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 16.4 | 73 | male | 3 | 16 | 5.8 | 6 | entrectinib 600 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:57.020383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504247 | REC_0000745 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 2.8 | 59 | female | 1 | 49 | 6.9 | 8 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSS | 2026-03-15T05:35:57.020632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649795 | REC_0000746 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 5.3 | 72 | female | 0 | 31 | 4.3 | 0 | osimertinib 80 mg daily | 18.1 | true | MSS | 2026-03-15T05:35:57.020867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889411 | REC_0000747 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 9.8 | 79 | female | 2 | 8 | 6.2 | 1 | osimertinib 80 mg daily | 19.8 | false | MSS | 2026-03-15T05:35:57.021099+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765388 | REC_0000748 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 7 | 63 | female | 0 | 45 | 5.2 | 5 | pembrolizumab 200 mg q3w | 8 | true | MSS | 2026-03-15T05:35:57.021334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828854 | REC_0000749 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.7 | 68 | female | 1 | 19 | 4.5 | 5 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:57.021571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690209 | REC_0000750 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 16.7 | 73 | female | 0 | 22 | 6.9 | 8 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:57.021805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934702 | REC_0000751 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 12.5 | 55 | female | 1 | 11 | 5.8 | 1 | entrectinib 600 mg daily | 14.8 | true | MSI-H | 2026-03-15T05:35:57.022043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681432 | REC_0000752 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 14.6 | 66 | female | 0 | 11 | 6 | 4 | entrectinib 600 mg daily | 4.9 | true | MSI-H | 2026-03-15T05:35:57.022286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836661 | REC_0000753 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 14.8 | 77 | female | 2 | 17 | 3.7 | 6 | alectinib 600 mg BID | 19.3 | false | MSS | 2026-03-15T05:35:57.022533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429088 | REC_0000754 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.9 | 68 | female | 0 | 10 | 6.5 | 4 | entrectinib 600 mg daily | 15.1 | true | MSS | 2026-03-15T05:35:57.022770+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659474 | REC_0000755 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 6.5 | 66 | female | 1 | 3 | 5.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:57.023152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353607 | REC_0000756 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.9 | 63 | female | 1 | 11 | 5.7 | 6 | entrectinib 600 mg daily | 6.3 | false | MSI-H | 2026-03-15T05:35:57.023427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533468 | REC_0000757 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 8.3 | 70 | female | 2 | 12 | 6 | 5 | pembrolizumab 200 mg q3w | 11.5 | false | MSS | 2026-03-15T05:35:57.023691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958724 | REC_0000758 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 37 | 12.4 | 62 | male | 0 | 19 | 3.5 | 5 | sotorasib 960 mg daily | 18.5 | true | MSI-H | 2026-03-15T05:35:57.023958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667337 | REC_0000759 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 8.5 | 65 | female | 1 | 10 | 4.4 | 3 | pembrolizumab 200 mg q3w | 6.6 | true | MSS | 2026-03-15T05:35:57.024283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969134 | REC_0000760 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 14.4 | 62 | male | 1 | 15 | 4.5 | 3 | sotorasib 960 mg daily | 4.7 | true | MSS | 2026-03-15T05:35:57.024567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553107 | REC_0000761 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 6.4 | 87 | female | 1 | 11 | 5 | 2 | osimertinib 80 mg daily | 21.9 | true | MSS | 2026-03-15T05:35:57.024836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784258 | REC_0000762 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 17.8 | 64 | male | 0 | 15 | 6.7 | 7 | alectinib 600 mg BID | 11.1 | false | MSS | 2026-03-15T05:35:57.025104+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741054 | REC_0000763 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 6.6 | 61 | male | 1 | 18 | 4.2 | 4 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.025360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200565 | REC_0000764 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 7.2 | 60 | female | 1 | 12 | 4.6 | 6 | entrectinib 600 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:57.025603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375238 | REC_0000765 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 15.8 | 66 | female | 0 | 23 | 6.1 | 7 | alectinib 600 mg BID | 7 | true | MSS | 2026-03-15T05:35:57.025844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639803 | REC_0000766 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 8.4 | 63 | female | 1 | 15 | 6.6 | 5 | osimertinib 80 mg daily | 11 | true | MSS | 2026-03-15T05:35:57.026085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747129 | REC_0000767 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 6.6 | 62 | male | 0 | 16 | 4.5 | 5 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:57.026330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967554 | REC_0000768 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 10 | 58 | female | 0 | 20 | 5.5 | 2 | pembrolizumab 200 mg q3w | 25.7 | false | MSI-H | 2026-03-15T05:35:57.026723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188200 | REC_0000769 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 14.3 | 72 | female | 2 | 3 | 5.8 | 6 | sotorasib 960 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:57.026980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705956 | REC_0000770 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 15.8 | 67 | female | 1 | 13 | 4.9 | 8 | alectinib 600 mg BID | 5.6 | false | MSS | 2026-03-15T05:35:57.027237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411843 | REC_0000771 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 8.8 | 58 | male | 1 | 19 | 4.8 | 4 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.027504+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843610 | REC_0000772 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 13.7 | 69 | female | 1 | 13 | 5.4 | 5 | sotorasib 960 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:57.027800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467348 | REC_0000773 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 10.9 | 77 | female | 3 | 9 | 7.3 | 3 | entrectinib 600 mg daily | 8.5 | false | MSI-H | 2026-03-15T05:35:57.028121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794676 | REC_0000774 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12.7 | 56 | female | 0 | 18 | 7.4 | 5 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:57.028431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757480 | REC_0000775 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 4.3 | 59 | male | 0 | 12 | 8.1 | 2 | pembrolizumab 200 mg q3w | 24.9 | true | MSS | 2026-03-15T05:35:57.028717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262941 | REC_0000776 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 6.8 | 58 | female | 0 | 18 | 6 | 6 | pembrolizumab 200 mg q3w | 14.8 | true | MSS | 2026-03-15T05:35:57.028987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535361 | REC_0000777 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 15.1 | 67 | female | 0 | 16 | 8.2 | 9 | osimertinib 80 mg daily | 18.5 | true | MSI-H | 2026-03-15T05:35:57.029233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466225 | REC_0000778 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.2 | 70 | female | 1 | 11 | 5.7 | 1 | osimertinib 80 mg daily | 27.7 | false | MSS | 2026-03-15T05:35:57.029480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389538 | REC_0000779 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 2.9 | 79 | male | 1 | 21 | 6.9 | 2 | pembrolizumab 200 mg q3w | 15.1 | true | MSS | 2026-03-15T05:35:57.029722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164341 | REC_0000780 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 31 | 9.5 | 76 | female | 1 | 4 | 4.8 | 0 | alectinib 600 mg BID | 23.9 | false | MSS | 2026-03-15T05:35:57.029967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467106 | REC_0000781 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 12.2 | 66 | female | 1 | 10 | 2.3 | 7 | alectinib 600 mg BID | 13.8 | true | MSS | 2026-03-15T05:35:57.030310+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692650 | REC_0000782 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 15.5 | 81 | female | 0 | 15 | 4.8 | 8 | entrectinib 600 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:35:57.030557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811153 | REC_0000783 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13.5 | 66 | female | 0 | 16 | 5.8 | 7 | osimertinib 80 mg daily | 17.2 | true | MSS | 2026-03-15T05:35:57.030799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627155 | REC_0000784 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 12.7 | 65 | female | 0 | 14 | 7.1 | 5 | alectinib 600 mg BID | 11.4 | false | MSS | 2026-03-15T05:35:57.031046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461406 | REC_0000785 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.7 | 75 | female | 1 | 15 | 4.8 | 4 | sotorasib 960 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:57.031291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216014 | REC_0000786 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 10.9 | 76 | female | 1 | 7 | 7.3 | 1 | pembrolizumab 200 mg q3w | 12.8 | true | MSI-H | 2026-03-15T05:35:57.031530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402687 | REC_0000787 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 8.9 | 65 | male | 1 | 8 | 7.6 | 8 | entrectinib 600 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:57.031769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843333 | REC_0000788 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 8.2 | 47 | female | 0 | 8 | 6.2 | 7 | entrectinib 600 mg daily | 5 | false | MSS | 2026-03-15T05:35:57.032006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976163 | REC_0000789 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 17.9 | 63 | female | 0 | 26 | 6.4 | 2 | sotorasib 960 mg daily | 25.5 | true | MSI-H | 2026-03-15T05:35:57.032305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546756 | REC_0000790 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 14.4 | 58 | male | 1 | 2 | 4.9 | 2 | alectinib 600 mg BID | 15.4 | true | MSI-H | 2026-03-15T05:35:57.032563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619234 | REC_0000791 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.6 | 64 | male | 0 | 34 | 6.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.2 | true | MSS | 2026-03-15T05:35:57.032809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166568 | REC_0000792 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 13 | 71 | female | 2 | 17 | 5.1 | 2 | osimertinib 80 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:57.033057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512888 | REC_0000793 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 11.8 | 65 | male | 0 | 18 | 7.4 | 6 | entrectinib 600 mg daily | 8.8 | true | MSS | 2026-03-15T05:35:57.033299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307312 | REC_0000794 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.4 | 71 | female | 0 | 51 | 3.1 | 8 | carboplatin + paclitaxel + pembrolizumab | 12.3 | true | MSS | 2026-03-15T05:35:57.033639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527428 | REC_0000795 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 38 | 10.7 | 77 | female | 1 | 29 | 6.5 | 8 | alectinib 600 mg BID | 9.3 | false | MSS | 2026-03-15T05:35:57.033887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275226 | REC_0000796 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 9.4 | 74 | female | 1 | 8 | 5.3 | 1 | osimertinib 80 mg daily | 26.6 | false | MSS | 2026-03-15T05:35:57.034122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412148 | REC_0000797 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 16.2 | 66 | female | 0 | 18 | 6.7 | 6 | pembrolizumab 200 mg q3w | 9.8 | true | MSI-H | 2026-03-15T05:35:57.034362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487481 | REC_0000798 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 3.2 | 65 | male | 0 | 40 | 6.5 | 2 | pembrolizumab 200 mg q3w | 23.3 | true | MSS | 2026-03-15T05:35:57.034596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661881 | REC_0000799 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.9 | 69 | female | 1 | 14 | 5 | 1 | osimertinib 80 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:35:57.034836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207148 | REC_0000800 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 13 | 67 | female | 1 | 24 | 4.4 | 2 | alectinib 600 mg BID | 25.7 | true | MSI-H | 2026-03-15T05:35:57.035072+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.